Author Archives: admin


Stem Cell Clinic > Articles by: admin

Stem Cell Bond Measure To Be Placed On November Ballot – California Globe

By Embryonic Stem Cells

On Monday, California Secretary of State Alex Padilla announced that a ballot measure to refund Californias stem cell agency received enough signatures and would be placed on the November 2020 ballot.

The measure, if passed, would refund the California Institute for Regenerative Medicine (CIRM) with a $5.5 billion bond to continue with stem cell research, facility construction, and training. According to the press release, much of the funding would specifically go towards research for Alzheimers, Parkinsons, stroke, epilepsy, and other brain and other central nervous system diseases and conditions.

With 685,534 signatures, 110% of the needed amount, Secretary Padilla can now officially announce the ballot placement once random sampling validates the required amount.

Stem cell research has remained controversial due the use of stem cells from human embryos, or embryonic stem cells. Federal funding for stem cell research was removed by former President George W. Bush in the 2000s, with his successor Barack Obama bringing research back in the 2010s. Despite the controversy, California created its own stem cell research institute after the passage of Proposition 71 in 2004, setting up CIRM. While still controversial, CIRMs immediate need of more funding , compounded by research quickly reducing the need to embryonic stem cells and advances in stem cell treatments for many older patients quickly brought in enough signatures for a refund initiative.

CIRM is close to shutting down, noted stem cell research advocate Gabrielle Hogan. This is badly needed funding that would pay for research for cures or repairing damage caused by Alzheimers and a number of other brain and memory related illnesses.

Its gotten a bad rap from some people because of the use of certain stem cells, but theyve mainly gone away from those that caused a furor twenty years ago. The focus is on saving people and treating people.

If we dont get this bond, which will fund us for a long time to come, then were screwed and we lose out on saving hundreds of thousands of people.

Others have continued to advocate for not continuing funding.

What if you treat someone who doesnt believe in abortion with embryonic stem cells, questioned Rita DAmico, a former nurse who opposed federal reintroduction of funding stem cell research ten years ago. It would be the same as using a medicine or treatment involving something deriving from the pig for a Muslim or Jewish patient, or giving a blood transfusion for a Jehovahs witness.

Its part of the belief, and if theyre still using it for treatments it can single some people out. This was what led it to the federal funding ban when Bush was in office after all.

The ballot measure, which has seen growing support in recent months, is expected to be validated by Secretary Padilla on Thursday.

Evan V. Symon is the Senior Editor for the California Globe. Prior to the Globe, he reported for the Pasadena Independent, the Cleveland Plain Dealer, and was head of the Personal Experiences section at Cracked. He can be reached at evan@californiaglobe.com.

View post:
Stem Cell Bond Measure To Be Placed On November Ballot - California Globe

Trending: Autologous Stem Cell Based Therapies 2020: Global Size, Supply-Demand, Product Type and End User Analysis To 2026 – Weekly Wall

By Embryonic Stem Cells

LOS ANGELES, United States: QY Research has recently published a report, titled Global Autologous Stem Cell Based Therapies Market Size, Status and Forecast 2020-2026. The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Autologous Stem Cell Based Therapies market. It informs readers about key trends and opportunities in the global Autologous Stem Cell Based Therapies market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Autologous Stem Cell Based Therapies market.

Key companies operating in the global Autologous Stem Cell Based Therapies market include , Regeneus, Mesoblast, Pluristem Therapeutics Inc, US STEM CELL, INC., Brainstorm Cell Therapeutics, Tigenix, Med cell Europe, Autologous Stem Cell Based Therapies

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1889061/global-autologous-stem-cell-based-therapies-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Autologous Stem Cell Based Therapies market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Autologous Stem Cell Based Therapies Market Segment By Type:

, Embryonic Stem Cell, Resident Cardiac Stem Cells, Umbilical Cord Blood Stem Cells Autologous Stem Cell Based Therapies

Global Autologous Stem Cell Based Therapies Market Segment By Application:

, Neurodegenerative Disorders, Autoimmune Diseases, Cardiovascular Diseases

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Autologous Stem Cell Based Therapies market.

Key companies operating in the global Autologous Stem Cell Based Therapies market include , Regeneus, Mesoblast, Pluristem Therapeutics Inc, US STEM CELL, INC., Brainstorm Cell Therapeutics, Tigenix, Med cell Europe, Autologous Stem Cell Based Therapies

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1889061/global-autologous-stem-cell-based-therapies-market

TOC

1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Autologous Stem Cell Based Therapies Revenue 1.4 Market by Type 1.4.1 Global Autologous Stem Cell Based Therapies Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Embryonic Stem Cell 1.4.3 Resident Cardiac Stem Cells 1.4.4 Umbilical Cord Blood Stem Cells 1.5 Market by Application 1.5.1 Global Autologous Stem Cell Based Therapies Market Share by Application: 2020 VS 2026 1.5.2 Neurodegenerative Disorders 1.5.3 Autoimmune Diseases 1.5.4 Cardiovascular Diseases 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends 2.1 Global Autologous Stem Cell Based Therapies Market Perspective (2015-2026) 2.2 Global Autologous Stem Cell Based Therapies Growth Trends by Regions 2.2.1 Autologous Stem Cell Based Therapies Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Autologous Stem Cell Based Therapies Historic Market Share by Regions (2015-2020) 2.2.3 Autologous Stem Cell Based Therapies Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Autologous Stem Cell Based Therapies Market Growth Strategy 2.3.6 Primary Interviews with Key Autologous Stem Cell Based Therapies Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Autologous Stem Cell Based Therapies Players by Market Size 3.1.1 Global Top Autologous Stem Cell Based Therapies Players by Revenue (2015-2020) 3.1.2 Global Autologous Stem Cell Based Therapies Revenue Market Share by Players (2015-2020) 3.1.3 Global Autologous Stem Cell Based Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Autologous Stem Cell Based Therapies Market Concentration Ratio 3.2.1 Global Autologous Stem Cell Based Therapies Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Autologous Stem Cell Based Therapies Revenue in 2019 3.3 Autologous Stem Cell Based Therapies Key Players Head office and Area Served 3.4 Key Players Autologous Stem Cell Based Therapies Product Solution and Service 3.5 Date of Enter into Autologous Stem Cell Based Therapies Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026) 4.1 Global Autologous Stem Cell Based Therapies Historic Market Size by Type (2015-2020) 4.2 Global Autologous Stem Cell Based Therapies Forecasted Market Size by Type (2021-2026) 5 Market Size by Application (2015-2026) 5.1 Global Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 5.2 Global Autologous Stem Cell Based Therapies Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Autologous Stem Cell Based Therapies Market Size (2015-2020) 6.2 Autologous Stem Cell Based Therapies Key Players in North America (2019-2020) 6.3 North America Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 6.4 North America Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 7 Europe 7.1 Europe Autologous Stem Cell Based Therapies Market Size (2015-2020) 7.2 Autologous Stem Cell Based Therapies Key Players in Europe (2019-2020) 7.3 Europe Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 7.4 Europe Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 8 China 8.1 China Autologous Stem Cell Based Therapies Market Size (2015-2020) 8.2 Autologous Stem Cell Based Therapies Key Players in China (2019-2020) 8.3 China Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 8.4 China Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 9 Japan 9.1 Japan Autologous Stem Cell Based Therapies Market Size (2015-2020) 9.2 Autologous Stem Cell Based Therapies Key Players in Japan (2019-2020) 9.3 Japan Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 9.4 Japan Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Autologous Stem Cell Based Therapies Market Size (2015-2020) 10.2 Autologous Stem Cell Based Therapies Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 10.4 Southeast Asia Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 11 India 11.1 India Autologous Stem Cell Based Therapies Market Size (2015-2020) 11.2 Autologous Stem Cell Based Therapies Key Players in India (2019-2020) 11.3 India Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 11.4 India Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Autologous Stem Cell Based Therapies Market Size (2015-2020) 12.2 Autologous Stem Cell Based Therapies Key Players in Central & South America (2019-2020) 12.3 Central & South America Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 12.4 Central & South America Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 13 Key Players Profiles 13.1 Regeneus 13.1.1 Regeneus Company Details 13.1.2 Regeneus Business Overview 13.1.3 Regeneus Autologous Stem Cell Based Therapies Introduction 13.1.4 Regeneus Revenue in Autologous Stem Cell Based Therapies Business (2015-2020)) 13.1.5 Regeneus Recent Development 13.2 Mesoblast 13.2.1 Mesoblast Company Details 13.2.2 Mesoblast Business Overview 13.2.3 Mesoblast Autologous Stem Cell Based Therapies Introduction 13.2.4 Mesoblast Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.2.5 Mesoblast Recent Development 13.3 Pluristem Therapeutics Inc 13.3.1 Pluristem Therapeutics Inc Company Details 13.3.2 Pluristem Therapeutics Inc Business Overview 13.3.3 Pluristem Therapeutics Inc Autologous Stem Cell Based Therapies Introduction 13.3.4 Pluristem Therapeutics Inc Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.3.5 Pluristem Therapeutics Inc Recent Development 13.4 US STEM CELL, INC. 13.4.1 US STEM CELL, INC. Company Details 13.4.2 US STEM CELL, INC. Business Overview 13.4.3 US STEM CELL, INC. Autologous Stem Cell Based Therapies Introduction 13.4.4 US STEM CELL, INC. Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.4.5 US STEM CELL, INC. Recent Development 13.5 Brainstorm Cell Therapeutics 13.5.1 Brainstorm Cell Therapeutics Company Details 13.5.2 Brainstorm Cell Therapeutics Business Overview 13.5.3 Brainstorm Cell Therapeutics Autologous Stem Cell Based Therapies Introduction 13.5.4 Brainstorm Cell Therapeutics Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.5.5 Brainstorm Cell Therapeutics Recent Development 13.6 Tigenix 13.6.1 Tigenix Company Details 13.6.2 Tigenix Business Overview 13.6.3 Tigenix Autologous Stem Cell Based Therapies Introduction 13.6.4 Tigenix Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.6.5 Tigenix Recent Development 13.7 Med cell Europe 13.7.1 Med cell Europe Company Details 13.7.2 Med cell Europe Business Overview 13.7.3 Med cell Europe Autologous Stem Cell Based Therapies Introduction 13.7.4 Med cell Europe Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.7.5 Med cell Europe Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

More here:
Trending: Autologous Stem Cell Based Therapies 2020: Global Size, Supply-Demand, Product Type and End User Analysis To 2026 - Weekly Wall

Mini-Organ Research Reveals What COVID-19 Does to the Body – Futurism

By Stem Cell Doctors

In order to understand how COVID-19 spreads throughout the body, ravaging it in myriad ways, doctors are growing miniature balls or organ-like tissue called organoids, and infecting them again and again.

The results, Nature News reports, are particularly troubling: the miniature lungs, livers, kidneys, hearts, intestines all showed signs of damage. The series of studies reveals with shocking clarity that COVID-19 can cause far more than a lung infection.

Of course, thats not exactly news. This harrowing list of survivors and medical workers horror stories gathered by SFGate includes heart attacks, strokes, long-term lung damage, incontinence, skin damage, and other serious complications for supposed mild cases of the coronavirus:

Thats just one of the many, many stories they gathered about the ways a road to recovery from COVID-19 is neither linear nor something that shouldnt be feared.

That said, for all their benefits, organoids are still imperfect. Per Nature, theyre far more simplistic than a full-sized organ. And because theyre not all connected in the same body, doctors can only use them to study the impacts on a single organ in isolation.

We know the cells die but we dont know how, Weill Cornell Medicine stem cell biologist Shuibing Chen told Nature of her study on miniature lungs.

Even though questions remain, its clear those impacts are serious. Various studies found that the coronavirus caused serious damage in several organs, and may lead to indirect damage in others. It also became clear that the coronavirus can infect and spread through blood vessels, leading to a more serious, widespread case.

To figure that out, biologists will need to develop more sophisticated and realistic organoids and try their experiments again, Nature reports.

It is too early to say how relevant they are, Bart Haagmans, an Erasmus MC virologist who ran a study on gut organoids, told Nature.

See the original post:
Mini-Organ Research Reveals What COVID-19 Does to the Body - Futurism

Who is Nick Cordero and how is he doing after his coronavirus battle? – The Sun

By Stem Cell Doctors

BROADWAY star Nick Cordero contracted coronavirus on March 20 of this year according to his wife Amanda Kloots.

The Tony Award-nominated actorfor Bullets over Broadway has been in the ICU since late March, with his other half keeping fans updated on his progress.

5

Earlier this year in May, Amanda tearfully revealed that Nick's condition was "going a little downhill."

Nick Cordero is a Canadian Broadway actor.

The 41-year-old has performed in the likes of A Bronx Tale The Musical, Waitress, and Rock of Ages.

He has collected several accolades for his theatre work over the years from the Outer Critics Circle and the Theatre World Awards.

Nick caught coronavirus earlier in March this year and has faced a series of ups and downs since he contracted the virus.

He was hospitalized in ICU after doctors first misdiagnosed him with pneumonia.

Nick has suffered a variety of complications as a result of COVID-19.

Doctors were not only forced to amputate his right leg because of blood clots, but the Broadway star has also had to undergo stem cell treatment to strengthen his lungs.

Nick's wife Amanda, who is single-handedly raising their one-year-old son Elvis while Nick is ill, regularly takes to Instagram to update fans on his condition.

5

In May, Amanda tearfully shared that Nick's condition was worsening.

"Nick has had a bad morning. Unfortunately, things are going a little downhill at the moment," she shared.

She added "I know that this virus is not going to get him down.

"This is not how his story ends. So just keep us in your thoughts and prayers, thank you."

A week beforehand, she announced that Nick was finally conscious after a month-long coma.

"This infection that is leftover from when he went into septic shock the last time is still in his lungs and just kind of sitting there. They are doing everything they can to clean it out every day but its just not getting better.

5

The mom-of-one also told fans doctors could "lower his vent settings" once the infection goes away.

That will begin the process of trying to get him breathing on his own.

She added: They are cleaning him out every day and hes on antibiotics, so it can happen and its gonna happen because like Ive said from the beginning, the doctor told me from the beginning, if we have a positive attitude, there are options.

"This infection is gonna go away and he is gonna get off that ventilator. And thats the only mindset that I have right now.

Nick is fighting for his life every day in that ICU and I know he isnt giving up. Were not giving up. Nobody is giving up.

Amanda, 38, recently updated fans that husband Nickhad a "great day" after visiting the actor at Cedars-Sinai hospital in LA on Sunday.

She told her Instagram followers: "He was having such a great day.

"He was more alert than I've seen him in a while and he was really following [with] his eyes a lot."

5

Amanda also revealed the sweet "little tradition" she has during her hospital visits to see Nick - playing and singing along to seventies track Our House by Crosby, Stills, Nash & Young.

She added: "I say a big prayer, hold his hand and give him a kiss and tell him we will live together in our house one day and keep fighting and it's going to happen."

5

Nick has spent a total of 82 days in ICU since he was infected with the coronavirus.

Nick's good day comes as a morale boost after Amanda revealed that a CT scan on his lungs confirmed that he would not survive a lung transplant.

Exclusive

Exclusive

"You feel like sometimes there's lots of hope and then sometimes there's not as much hope. We're basically trying to see if we can get him stable and strong enough to have more options," she said.

"It's monotonous and hard on a daily basis - very, very hard."

Read the original here:
Who is Nick Cordero and how is he doing after his coronavirus battle? - The Sun

My Friend Was Struck by ALS. Heres How Hes Fighting Back – WIRED

By Stem Cell Doctors

Brian Wallach's left hand cramped and he dropped his pen. Ten minutes later, it happened again. Annoying. He'd spent months preparing for this case. He'd joined the US Attorney's Office, a dream job, almost three years earlier. He was in the midst of prosecuting the surviving member of a group that had smuggled guns into Chicago from Indiana. The trial was a few weeks away. And now these cramps. He chalked it up to stress and moved on.

That was April 2017. On July 31, Brian and his wife, Sandra Abrevaya, had their second daughter, jaundiced but otherwise healthy, so all three stayed in the hospital a week. That's when Brian started coughing, barking, unable to finish a sentence. Sandra told him to see a doctor, so he did. He ticked off every symptom he could think of: the cough, the cramp, and also a muscle twitch in his left arm.

That physician sent Brian to a neurologist the next day. The neurologist talked through Brian's symptoms, looked at his tongueit was subtly undulating, something Brian hadn't noticed. The doctor then told him the news: He likely had amyotrophic lateral sclerosis. ALS. Lou Gehrig's disease. If he was right, the doctor said, Brian had approximately six months to live.

That was the same day Sandra and their daughter had come home from the hospital. Brian barely knew what ALS was. It seemed impossible that it would have found him, much less imposed so strict a deadline.

Brian's first call on the drive home was not to Sandra but to Nick Morris, a neurologist at the University of Maryland and a friend from college. Before he could tell Sandra the news, he needed someone to help him process it. Nick obliged, explaining that there's no one definitive test for ALSin fact, a conclusive diagnosis often requires a monthslong process of elimination.

Sandra called in the middle of that conversation, and Brian switched over. She caught something in his voice. No, everything wasn't OK, he told her. No, he couldn't say it over the phone. Yes, he was on his way home.

Sandra paced while the girls napped. When he arrived she ran out to the car and jumped into the passenger seat. Nick was still on speakerphone. I need you to get off the phone because I don't know what's going on, Sandra said to them both. And then Brian told her.

That's not that bad, right?

No, Brian replied. It is.

I'll spare you some suspense. The neurologist was right about ALS, albeit for incomplete reasons, but he was wrong about the timetable. Three years later Brian is still alive.

ALS is a cruel disease. Motor neurons in the brain and spinal cord gradually degrade and then die, robbing the sufferer of control over their muscles. Eventually patients cannot move or speak or eat or breathe. There is no cure and, except in a minority of inherited cases, no known cause. Once symptoms appearin an arm or a leg or a handthe typical survival rate is three to five years. It is fatal in virtually all cases.

Brian was one of roughly 5,000 people in the US to receive an ALS diagnosis in 2017. He's one of more than 16,000 patients living with the disease in the country today. Each has faced some version of Brian's moment in the car: mortality in sharp relief. A loved one at home who doesn't yet know. A decision about how to spend whatever time they have left.

Brian and I have known each other for three decades. Our lives have played out as variations on the same theme: good schools, bad work-life balance, two kids, settled down hundreds of miles from where we grew up. He and Sandra told me this story when I visited them last spring. We were sitting in a bedroom addition of their suburban Chicago home, built with a ramp for the inevitable day that Brian's disease will confine him to a wheelchair.

View post:
My Friend Was Struck by ALS. Heres How Hes Fighting Back - WIRED

Family of 18-year-old Doncaster boy who died of cancer raise thousands for charities that helped him – Doncaster Free Press

By Stem Cell Doctors

Joel Esan, 18, from Bessacarr, Doncaster sadly passed away on June 14, 2020 after he had been fighting a rare type of leukaemia, known as Acute Leukaemia of Ambiguous Lineage for the last two years.

Despite multiple rounds of chemotherapy, radiotherapy and a stem cell transplant from his mother, Joels aggressive form of cancer returned twice since he was first diagnosed at 16-years-old in 2018.

In April earlier this year, doctors told Joel that he only had three months to live because the leukaemia had returned and the disease had mutated meaning no further treatment could cure him.

Joel's final wish was for his family to raise money for the organisations that cared for him.

The 18-year-olds final wish was for his family to raise money for the charities that helped care for him, in particular The Teenage Cancer Trust, Clic Sargent, Laurens Legacy, Starlight and Anthony Nolan.

Joels relatives have fundraised 5,251 in just two days through their dedicated donation page to ensure other families and people like Joel can access help and support when they most need it.

His brother, Patrice Esan explained how it feels to have raised more than half of their 10,000 target.

"It just makes us so happy because we know Joel would have wanted us to raise this for those charities, Patrice said.

Joel pictured next to his sister, Charlotte, sister-in-law Zoe and brothers Patrice, Lee and Lewis.

"He would be happy looking down on us knowing we are doing a good job for him to continue his legacy and to help other people.

Joels family have expressed their thanks for the Haematology ward at The Royal Hallamshire Hospital in Sheffield who helped care for him and made the entire experience a touch less difficult to bear.

The 18-year-old spent his last moments surrounded by his loved ones in his family home.

Patrice added: He fought so hard and everything he did, he never complained about a single thing which was obviously a credit to him.

Joel (right) next to his brother Patrice (centre) and dad Femi (left).

"Even in his last moments he spoke to us and asked us to get out of bed and in those moments, he stood up in mine and my sister's arms and passed away in our arms.

"He kind of used his last strength to get up which was quite a sudden thing to happen and it was nice as a family to be together and to use his last strength to be with us.

"He was the best brother you could ask for.

Joels relatives are now urging people from Black, Asian and minority ethnic backgrounds (BAME) to register to donate their stem cells with Anthony Nolan, a charity which has a register for those who are willing to donate their stem cells to help people with blood cancers.

Its after Joel was unable to find a 100% match for his transplant and instead received cells from his Mum who was only a 50% match, which made it less effective.

White Europeans have almost 70% chance of finding a stem cell donor, while BAME people have less than 20% of finding a successful match according to Anthony Nolan.

Original post:
Family of 18-year-old Doncaster boy who died of cancer raise thousands for charities that helped him - Doncaster Free Press

Global Regenerative Medicine Market Demands, Key Players, Growth, Size and Forecast with Impact of COVID-19 (2020-2024) – Jewish Life News

By Embryonic Stem Cells

Global Regenerative Medicine Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024), provides an in-depth analysis of the global regenerative medicine market with description of market sizing and growth. The analysis includes market by value, by product, by material and by region. Furthermore, the report also provides detailed product analysis, material analysis and regional analysis.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. Growth of the overall global regenerative medicine market has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Some of the major players operating in the global Regenerative Medicine Market are Novartis AG, Medtronic Plc, Bristol Myers Squibb (Celgene Corporation) and Smith+Nephew (Osiris Therapeutics, Inc.), whose company profiling has been done in the report. Furthermore, in this segment of the report, business overview, financial overview and business strategies of the respective companies are also provided.

Region Coverage

Company Coverage

Executive Summary

Regenerative medicines emphasis on regeneration or replacement of tissues, cells or organs of human body to cure the problem caused by disease or injury. The treatment fortify human cells to heal up or transplant stem cells into the body to regenerate lost tissues or organs or to recover impaired functionality. There are three types of stem cells that can be used in regenerative medicine: somatic stem cells, embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells).

The regenerative medicine also has the capability to treat chronic diseases and conditions, including Alzheimers, diabetes, Parkinsons, heart disease, osteoporosis, renal failure, spinal cord injuries, etc. Regenerative medicines can be bifurcated into different product type i.e., cell therapy, tissue engineering, gene therapy and small molecules and biologics. In addition, on the basis of material regenerative medicine can be segmented into biologically derived material, synthetic material, genetically engineered materials and pharmaceuticals.

Get Free Sample Copy of this Research Report at https://www.marketreportsonline.com/contacts/requestsample.php?name=813167

The global regenerative medicine market has surged at a progressive rate over the years and the market is further anticipated to augment during the forecasted years 2020 to 2024. The market would propel owing to numerous growth drivers like growth in geriatric population, rising global healthcare expenditure, increasing diabetic population, escalating number of cancer patients, rising prevalence of cardiovascular disease and surging obese population.

Though, the market faces some challenges which are hindering the growth of the market. Some of the major challenges faced by the industry are: legal obligation and high cost of treatment. Whereas, the market growth would be further supported by various market trends like three dimensional bioprinting , artificial intelligence to advance regenerative medicine, etc.

Table of Contents

Direct Purchase of this Research Report at (Single User License: US $ 900) https://www.marketreportsonline.com/contacts/purchase.php?name=813167

List of Tables

Table 1: Global Regenerative Medicine Market Players: A Financial Comparison; 2019

List of Figures.

See the original post here:
Global Regenerative Medicine Market Demands, Key Players, Growth, Size and Forecast with Impact of COVID-19 (2020-2024) - Jewish Life News

COVID 19 to Lead the Sales of Adipose Tissue-derived Stem Cells to Register Stellar Growth in the Next 10 Years – Personal Injury Bureau UK

By Embryonic Stem Cells

Adipose tissue is rich in multi potent stem cells that have the capability to differentiate into a number of cell types including adipocytes, osteocytes, chondrocytes and others, in vitro. These Adipose Tissue-derived Stem Cells are used for a number of applications including stem cell differentiation studies, regenerative medicine, cell therapy, tissue engineering and development of induced pluripotent stem cell lineage. Adult stem cells such as the Adipose Tissue-derived Stem Cells have a very good potential for regenerative medicine. The Adipose Tissue-derived Stem Cells show higher yields compared with other stem cell sources. Some of the regenerative medicine applications using Adipose Tissue-derived Stem Cells include skin, bone and cartilage regeneration.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/25831

Although, Adipose Tissue-derived Stem Cells have the ability to differentiate into different cell types in vitro, unlike the embryonic stem cells they lack the ability to differentiate into all types of organs and tissues of the body. Derivation of stem cells from adipose tissue have a number of advantages including that fat tissue contain 100 to 1000 times more mesenchymal stem cells than the bone marrow. Furthermore the method of collection of fat tissue is relatively easier and is less invasive than that of bone marrow collection. Although Adipose Tissue-derived Stem Cells have a potential to be used in cell-based therapy, there are a number of challenges the Adipose Tissue-derived Stem Cells market has to face. Some of the challenge include the safety issue for the clinical use of Adipose Tissue-derived Stem Cells, development and differentiation of the cells, delivery of the cells in vivo and immune response after the transplant.

The global Adipose Tissue-derived Stem Cells market is segmented based on product type and end user. Based on product type the Adipose Tissue-derived Stem Cells can be categorized into cell line and reagent & kits. Cell line can be further classified based on the source of the adipose tissue such as human and rodents. Based on reagents the Adipose Tissue-derived Stem Cells market is further classified as media & sera and kits. Based on application the Adipose Tissue-derived Stem Cells market is classified into regenerative medicine, cell therapy, tissue engineering, and other applications such as cell differentiation studies and other similar research. End users of Adipose Tissue-derived Stem Cells market are biotechnology companies and academic and research institutes.

The Global Adipose Tissue-derived Stem Cells market is classified on the basis of product type, end user and region:

Based on the Product Type, Adipose Tissue-derived Stem Cells market is segmented into following:

Based on the application, Adipose Tissue-derived Stem Cells market is segmented into following:

Based on the end user, Adipose Tissue-derived Stem Cells market is segment as below:

Key participants operating in the Adipose Tissue-derived Stem Cells market are: Lonza, ThermoFisher Scientific, Celprogen, Inc, American CryoStem, Rexgenero Ltd, iXCells Biotechnologies, Merck KGaA, Lifeline Cell Technology, and others.

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/25831

Growing research activities using stem cells along with the growth of regenerative medicine and cell therapy the global Adipose Tissue-derived Stem Cells market is set to expand considerably during the forecast period. However, ethical concerns and stringent regulations may hinder the growth of the global Adipose Tissue-derived Stem Cells market.

On the basis of geography, global Adipose Tissue-derived Stem Cells market is segmented into six major regions that include North America, Latin America, Europe, Asia-Pacific excluding China, China and Middle East & Africa. North America is expected to be the most lucrative Adipose Tissue-derived Stem Cells market owing to increased research activity of stem cells. Furthermore government support for regenerative and stem cell based studies along with cell therapy studies is driving the growth of the Adipose Tissue-derived Stem Cells market in the region. Changing government regulations in china is supporting the research activity that supports the growth of the adipose tissue-derived stem cell market in the region at a considerable rate.

See the original post:
COVID 19 to Lead the Sales of Adipose Tissue-derived Stem Cells to Register Stellar Growth in the Next 10 Years - Personal Injury Bureau UK

Global Regenerative Medicine Market: Size and Forecast with Impact Analysis of COVID-19 (2020-2024) – Cole of Duty

By Embryonic Stem Cells

Scope of the Report

The report titled Global Regenerative Medicine Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024), provides an in-depth analysis of the global regenerative medicine market with description of market sizing and growth. The analysis includes market by value, by product, by material and by region. Furthermore, the report also provides detailed product analysis, material analysis and regional analysis.

Access the PDF sample of the report @https://www.orbisresearch.com/contacts/request-sample/4707408

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. Growth of the overall global regenerative medicine market has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Some of the major players operating in the global regenerative medicine market are Novartis AG, Medtronic Plc, Bristol Myers Squibb (Celgene Corporation) and Smith+Nephew (Osiris Therapeutics, Inc.), whose company profiling has been done in the report. Furthermore, in this segment of the report, business overview, financial overview and business strategies of the respective companies are also provided.

Region Coverage

North America Europe Asia Pacific ROW

Company Coverage

Novartis AG Medtronic Plc Bristol Myers Squibb (Celgene Corporation) Smith+Nephew (Osiris Therapeutics, Inc.)

Executive Summary

Regenerative medicines emphasis on regeneration or replacement of tissues, cells or organs of human body to cure the problem caused by disease or injury. The treatment fortify human cells to heal up or transplant stem cells into the body to regenerate lost tissues or organs or to recover impaired functionality. There are three types of stem cells that can be used in regenerative medicine: somatic stem cells, embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells).

The regenerative medicine also has the capability to treat chronic diseases and conditions, including Alzheimers, diabetes, Parkinsons, heart disease, osteoporosis, renal failure, spinal cord injuries, etc. Regenerative medicines can be bifurcated into different product type i.e., cell therapy, tissue engineering, gene therapy and small molecules and biologics. In addition, on the basis of material regenerative medicine can be segmented into biologically derived material, synthetic material, genetically engineered materials and pharmaceuticals.

The global regenerative medicine market has surged at a progressive rate over the years and the market is further anticipated to augment during the forecasted years 2020 to 2024. The market would propel owing to numerous growth drivers like growth in geriatric population, rising global healthcare expenditure, increasing diabetic population, escalating number of cancer patients, rising prevalence of cardiovascular disease and surging obese population.

Though, the market faces some challenges which are hindering the growth of the market. Some of the major challenges faced by the industry are: legal obligation and high cost of treatment. Whereas, the market growth would be further supported by various market trends like three dimensional bioprinting , artificial intelligence to advance regenerative medicine, etc.

Browse the full report @https://www.orbisresearch.com/reports/index/global-regenerative-medicine-market-size-and-forecast-with-impact-analysis-of-covid-19-2020-2024

Table of Contents

1. Executive Summary

2. Introduction

2.1 Regenerative Medicine: An Overview 2.2 Regeneration in Humans: An Overview 2.3 Expansion in Peripheral Industries of Regenerative Medicine 2.4 Approval System for Regenerative Medicine Products 2.5 Regenerative Medicine Segmentation

3. Global Market Analysis

3.1 Global Regenerative Medicine Market: An Analysis

3.1.1 Global Regenerative Medicine Market by Value 3.1.2 Global Regenerative Medicine Market by Products (Cell Therapy, Tissue Engineering, Gene Therapy and Small Molecules and Biologics) 3.1.3 Global Regenerative Medicine Market by Material (Biologically Derived Material, Synthetic Material, Genetically Engineered Materials and Pharmaceuticals) 3.1.4 Global Regenerative Medicine Market by Region (North America, Europe, Asia Pacific and ROW)

3.2 Global Regenerative Medicine Market: Product Analysis

3.2.1 Global Cell Therapy Regenerative Medicine Market by Value 3.2.2 Global Tissue Engineering Regenerative Medicine Market by Value 3.2.3 Global Gene Therapy Regenerative Medicine Market by Value 3.2.4 Global Small Molecules and Biologics Regenerative Medicine Market by Value

3.3 Global Regenerative Medicine Market: Material Analysis

3.3.1 Global Biologically Derived Material Market by Value 3.3.2 Global Synthetic Material Market by Value 3.3.3 Global Genetically Engineered Materials Market by Value 3.3.4 Global Regenerative Medicine Pharmaceuticals Market by Value

4. Regional Market Analysis

4.1 North America Regenerative Medicine Market: An Analysis 4.1.1 North America Regenerative Medicine Market by Value

4.2 Europe Regenerative Medicine Market: An Analysis 4.2.1 Europe Regenerative Medicine Market by Value

4.3 Asia Pacific Regenerative Medicine Market: An Analysis 4.3.1 Asia Pacific Regenerative Medicine Market by Value

4.4 ROW Regenerative Medicine Market: An Analysis 4.4.1 ROW Regenerative Medicine Market by Value

5. COVID-19

5.1 Impact of Covid-19 5.2 Response of Industry to Covid-19 5.3 Variation in Organic Traffic 5.4 Regional Impact of COVID-19

6. Market Dynamics

6.1 Growth Drivers 6.1.1 Growth in Geriatric Population 6.1.2 Rising Global Healthcare Expenditure 6.1.3 Increasing Diabetic Population 6.1.4 Escalating Number of Cancer Patients 6.1.5 Rising Prevalence of Cardiovascular Disease 6.1.6 Surging Obese Population

6.2 Challenges 6.2.1 Legal Obligation 6.2.2 High Cost of Treatment

6.3 Market Trends 6.3.1 3D Bio-Printing 6.3.2 Artificial Intelligence to Advance Regenerative Medicine

7. Competitive Landscape

7.1 Global Regenerative Medicine Market Players: A Financial Comparison 7.2 Global Regenerative Medicine Market Players by Research & Development Expenditure

8. Company Profiles

8.1 Bristol Myers Squibb (Celgene Corporation) 8.1.1 Business Overview 8.1.2 Financial Overview 8.1.3 Business Strategy

8.2 Medtronic Plc 8.2.1 Business Overview 8.2.2 Financial Overview 8.2.3 Business Strategy

8.3 Smith+Nephew (Osiris Therapeutics, Inc.) 8.3.1 Business Overview 8.3.2 Financial Overview 8.3.3 Business Strategy

8.4 Novartis AG 8.4.1 Business Overview 8.4.2 Financial Overview 8.4.3 Business Strategy

Direct purchase the report @ https://www.orbisresearch.com/contact/purchase-single-user/4707408

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector Costello Senior Manager Client Engagements 4144N Central Expressway, Suite 600, Dallas, Texas 75204, U.S.A. Phone No.: +1 (972)-362-8199; +91 895 659 5155

See the original post here:
Global Regenerative Medicine Market: Size and Forecast with Impact Analysis of COVID-19 (2020-2024) - Cole of Duty

Outlook on the Worldwide Regenerative Medicine Industry to 2024 – Rising Global Healthcare Expenditure Presents Opportunities – Yahoo Finance

By Embryonic Stem Cells

Dublin, June 22, 2020 (GLOBE NEWSWIRE) -- The "Global Regenerative Medicine Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

This report provides an in-depth analysis of the global regenerative medicine market with description of market sizing and growth. The analysis includes market by value, by product, by material and by region. Furthermore, the report also provides detailed product analysis, material analysis and regional analysis.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. Growth of the overall global regenerative medicine market has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Region Coverage:

Company Coverage:

Regenerative medicines emphasise on the regeneration or replacement of tissues, cells or organs of the human body to cure the problem caused by disease or injury. The treatment fortifies the human cells to heal up or transplant stem cells into the body to regenerate lost tissues or organs or to recover impaired functionality. There are three types of stem cells that can be used in regenerative medicine: somatic stem cells, embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells).

The regenerative medicine also has the capability to treat chronic diseases and conditions, including Alzheimer's, diabetes, Parkinson's, heart disease, osteoporosis, renal failure, spinal cord injuries, etc. Regenerative medicines can be bifurcated into different product type i.e., cell therapy, tissue engineering, gene therapy and small molecules and biologics. In addition, on the basis of material regenerative medicine can be segmented into biologically derived material, synthetic material, genetically engineered materials and pharmaceuticals.

The global regenerative medicine market has surged at a progressive rate over the years and the market is further anticipated to augment during the forecasted years 2020 to 2024. The market would propel owing to numerous growth drivers like growth in geriatric population, rising global healthcare expenditure, increasing diabetic population, escalating number of cancer patients, rising prevalence of cardiovascular disease and surging obese population.

Though, the market faces some challenges which are hindering the growth of the market. Some of the major challenges faced by the industry are: legal obligation and high cost of treatment. Whereas, the market growth would be further supported by various market trends like three dimensional bioprinting , artificial intelligence to advance regenerative medicine, etc.

Key Topics Covered:

1. Executive Summary

2. Introduction 2.1 Regenerative Medicine: An Overview 2.2 Regeneration in Humans: An Overview 2.3 Expansion in Peripheral Industries of Regenerative Medicine 2.4 Approval System for Regenerative Medicine Products 2.5 Regenerative Medicine Segmentation

3. Global Market Analysis 3.1 Global Regenerative Medicine Market: An Analysis 3.1.1 Global Regenerative Medicine Market by Value 3.1.2 Global Regenerative Medicine Market by Products (Cell Therapy, Tissue Engineering, Gene Therapy and Small Molecules and Biologics) 3.1.3 Global Regenerative Medicine Market by Material (Biologically Derived Material, Synthetic Material, Genetically Engineered Materials and Pharmaceuticals) 3.1.4 Global Regenerative Medicine Market by Region (North America, Europe, Asia Pacific and ROW)

3.2 Global Regenerative Medicine Market: Product Analysis 3.2.1 Global Cell Therapy Regenerative Medicine Market by Value 3.2.2 Global Tissue Engineering Regenerative Medicine Market by Value 3.2.3 Global Gene Therapy Regenerative Medicine Market by Value 3.2.4 Global Small Molecules and Biologics Regenerative Medicine Market by Value

3.3 Global Regenerative Medicine Market: Material Analysis 3.3.1 Global Biologically Derived Material Market by Value 3.3.2 Global Synthetic Material Market by Value 3.3.3 Global Genetically Engineered Materials Market by Value 3.3.4 Global Regenerative Medicine Pharmaceuticals Market by Value

4. Regional Market Analysis 4.1 North America Regenerative Medicine Market: An Analysis 4.2 Europe Regenerative Medicine Market: An Analysis 4.3 Asia Pacific Regenerative Medicine Market: An Analysis 4.4 ROW Regenerative Medicine Market: An Analysis

Story continues

5. COVID-19 5.1 Impact of Covid-19 5.2 Response of Industry to Covid-19 5.3 Variation in Organic Traffic 5.4 Regional Impact of COVID-19

6. Market Dynamics 6.1 Growth Drivers 6.1.1 Growth in Geriatric Population 6.1.2 Rising Global Healthcare Expenditure 6.1.3 Increasing Diabetic Population 6.1.4 Escalating Number of Cancer Patients 6.1.5 Rising Prevalence of Cardiovascular Disease 6.1.6 Surging Obese Population 6.2 Challenges 6.2.1 Legal Obligation 6.2.2 High Cost of Treatment 6.3 Market Trends 6.3.1 3D Bio-Printing 6.3.2 Artificial Intelligence to Advance Regenerative Medicine

7. Competitive Landscape 7.1 Global Regenerative Medicine Market Players: A Financial Comparison 7.2 Global Regenerative Medicine Market Players' by Research & Development Expenditure

8. Company Profiles 8.1 Bristol Myers Squibb (Celgene Corporation) 8.1.1 Business Overview 8.1.2 Financial Overview 8.1.3 Business Strategy 8.2 Medtronic Plc 8.2.1 Business Overview 8.2.2 Financial Overview 8.2.3 Business Strategy 8.3 Smith+Nephew (Osiris Therapeutics, Inc.) 8.3.1 Business Overview 8.3.2 Financial Overview 8.3.3 Business Strategy 8.4 Novartis AG 8.4.1 Business Overview 8.4.2 Financial Overview 8.4.3 Business Strategy

For more information about this report visit https://www.researchandmarkets.com/r/w15smu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

More:
Outlook on the Worldwide Regenerative Medicine Industry to 2024 - Rising Global Healthcare Expenditure Presents Opportunities - Yahoo Finance

→←